Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases

被引：6
|
作者：
Jiang, Tao [1 ,2 ]
Xu, Xiaobo [2 ]
Chen, Xiaojuan [3 ]
Ding, Ning [2 ]
Hu, Qin [4 ]
Zhou, Caicun [1 ]
Hu, Jie [2 ]
机构：
[1] Tongji Univ, Shanghai Pulm Hosp, Dept Oncol, Sch Med, Shanghai, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Dept Pulm Med, Shanghai Resp Res Inst, 180 Fenglin Rd, Shanghai 200032, Peoples R China
[3] Wenzhou Med Univ, Dept Gastroenterol, Wenzhou Clin Inst 3, Wenzhou Peoples Hosp, Wenzhou, Peoples R China
[4] Fudan Univ, Shanghai Resp Res Inst, Zhongshan Hosp, Dept Pathol, Shanghai, Peoples R China
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2020年 / 9卷 / 06期
基金：
中国国家自然科学基金;
关键词：
CELL LUNG-CANCER; ERLOTINIB; SURVIVAL;
D O I：
10.21037/tlcr-20-984
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2514 / 2517
页数：4
相关论文
共 50 条
  • [41] Treatment Response To Osimertinib In EGFR-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Series
    Li, Huiying
    Yu, Tingting
    Huang, Mingmin
    Guo, Aibin
    Qian, Xiaoping
    Yin, Zhenyu
    ONCOTARGETS AND THERAPY, 2019, 12 : 7785 - 7790
  • [42] Chemotherapy with or without immunotherapy or bevacizumab for EGFR-mutated lung cancer after progression on osimertinib
    White, M.
    Neal, J. W.
    Gardner, R. M.
    Cunanan, K. M.
    Das, M.
    Padda, S. K.
    Ramchandran, K.
    Chen, T. T.
    Wakelee, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S773 - S774
  • [43] Osimertinib in EGFR-Mutated Lung Cancer REPLY
    Herbst, Roy S.
    Wu, Yi-Long
    Tsuboi, Masahiro
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (07): : 675 - 676
  • [44] High-Dose Furmonertinib in Patients With EGFR-Mutated NSCLC and Leptomeningeal Metastases: A Prospective Real-World Study
    Chen, Haiyang
    Yang, Sen
    Wang, Lili
    Wu, Yingxi
    Wu, Yufeng
    Ma, Shuxiang
    He, Zhen
    Zhang, Cuicui
    Liu, Yang
    Tang, Haoran
    Dong, Hang
    Wang, Qiming
    JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (01) : 65 - 75
  • [45] Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
    Crowley, Fionnuala
    Fitzgerald, Bailey G.
    Bhardwaj, Aarti S.
    Siraj, Irine
    Smith, Cardinale
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (01):
  • [46] Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis
    Yi, Lilan
    Fan, Junsheng
    Qian, Ruolan
    Luo, Peng
    Zhang, Jian
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (01) : 284 - 294
  • [47] PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC
    Vokes, Natalie I.
    Le, Xiuning
    Yap, Timothy A.
    CLINICAL CANCER RESEARCH, 2024, 30 (18) : 3968 - 3970
  • [48] Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
    de Jager, Vincent D.
    Stigt, Jos A.
    Niemantsverdriet, Maarten
    ter Elst, Arja
    van der Wekken, Anthonie J.
    NPJ PRECISION ONCOLOGY, 2024, 8 (01)
  • [49] Gefitinib Approved for EGFR-Mutated NSCLC
    不详
    CANCER DISCOVERY, 2015, 5 (09) : 896 - 896
  • [50] Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
    Ye, Qiuyue
    Xu, Yan
    Zhao, Jing
    Gao, Xiaoxing
    Chen, Minjiang
    Pan, Ruili
    Zhong, Wei
    Wang, Mengzhao
    TRANSLATIONAL ONCOLOGY, 2023, 31
12345